The Binding Site

The Binding Site The Specialist Protein Company

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation. Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders. Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years. We are committed to working in collaboration with our partners and customers to lead the way in specialized medical diagnostics, ensuring we continue to make a difference together.

19/12/2025

From all of us at The Binding Site, we wish you a happy, healthy, and joyful holiday season!

ASH 2025 brought together the global hematology community, providing us the opportunity to exchange knowledge and share ...
18/12/2025

ASH 2025 brought together the global hematology community, providing us the opportunity to exchange knowledge and share emerging insights in Multiple Myeloma diagnostics.

We’re grateful for the oral and poster sessions that showcased groundbreaking research, and conversations that continue to shape the future of monoclonal gammopathies. We look forward to building on these connections, strengthening our collaborations and continuing to drive diagnostic innovation into 2026.

New research using EXENT® System featured at ! The latest data from researchers in the United States, highlights how th...
08/12/2025

New research using EXENT® System featured at !

The latest data from researchers in the United States, highlights how the EXENT System can provide deeper insights into IgM monoclonal proteins in familial Waldenström’s macroglobulinemia (WM) cases.

We’re proud to see this work incorporating the EXENT System represented at ASH and look forward to exploring the findings further during Monday’s poster session (5:30 – 7:30 PM).

The landscape of plasma cell disorders continues to evolve, moving beyond the traditional ‘undetermined significance’ of...
08/12/2025

The landscape of plasma cell disorders continues to evolve, moving beyond the traditional ‘undetermined significance’ of MGUS towards growing recognition of monoclonal gammopathies of clinical significance (MGCS).

We are looking forward to attending today’s ASH session in OCCC - West Hall E2 (4:30–5:45 PM), where leading experts will share the latest insights on:

▪️ Diagnosing and managing POEMS syndrome
▪️ Understanding monoclonal gammopathy of renal significance (MGRS)
▪️ Addressing monoclonal gammopathy of neurologic significance (MGNS)

To understand more on MGCS, take a look at our dedicated MGCS webpage here: http://spr.ly/61877CBBb

Two posters presented at ASH 2025 highlight how pivotal the SLiM criteria have been in transforming myeloma care. For pa...
08/12/2025

Two posters presented at ASH 2025 highlight how pivotal the SLiM criteria have been in transforming myeloma care.

For patients with MGUS (poster 3972), the introduction of the SLiM criteria has led to increased evaluation for myeloma defining events and lower monoclonal protein at the time of first biopsy, showing that patients are being assessed earlier in their disease course.

In newly diagnosed myeloma patients (poster 6378), the rise in the use of SLiM biomarkers supported earlier diagnosis and resulted in fewer patients presenting with CRAB related organ damage.

Our scientific team is attending a poster session this evening, connecting with colleagues and discussing the latest adv...
07/12/2025

Our scientific team is attending a poster session this evening, connecting with colleagues and discussing the latest advances in the monoclonal gammopathy field.

Visit us at booth 2171 before 2pm tomorrow connect with our scientific team.

At this year’s ASH, researchers from the nationwide NoMoreMGUS project are challenging long-standing ‘undetermined signi...
07/12/2025

At this year’s ASH, researchers from the nationwide NoMoreMGUS project are challenging long-standing ‘undetermined significance’ in MGUS.

Across 31 Spanish hospitals, this large-scale study is exploring minimally invasive biomarkers to identify patients at higher risk of malignant transformation.

Early findings reveal that measuring circulating tumor cells (CTCs) alongside M-protein concentration and sFLC ratio can better identify patients at higher risk of transformation, helping define a new category of MGUS: monoclonal gammopathies of malignant significance.

We are looking forward to hearing more about it from Dr Bruno Paiva today at 12.15 in OCCC - West Hall E2.

At this year’s ASH, researchers from the nationwide NoMoreMGUS project are challenging long-standing ‘undetermined signi...
07/12/2025

At this year’s ASH, researchers from the nationwide NoMoreMGUS project are challenging long-standing ‘undetermined significance’ in MGUS.

Across 31 Spanish hospitals, this large-scale study is exploring minimally invasive biomarkers to identify patients at higher risk of malignant transformation.

Early findings reveal that measuring circulating tumor cells (CTCs) alongside M-protein concentration and sFLC ratio can better identify patients at higher risk of transformation, helping define a new category of MGUS: monoclonal gammopathies of malignant significance.

We are looking forward to hearing more about it from Dr Bruno Paiva today at 12.15 in OCCC - West Hall E2.

We are here at 2025! We are excited to kick off ASH 2025 and join the global hematology community to exchange knowledg...
06/12/2025

We are here at 2025!

We are excited to kick off ASH 2025 and join the global hematology community to exchange knowledge, share new insights, and advance education in Multiple Myeloma diagnostics.

Visit us at booth 2171 to connect with our scientific team.

New research using EXENT® System featured at ! The latest data from researchers in Oxford, UK, highlights how the EXENT...
06/12/2025

New research using EXENT® System featured at !

The latest data from researchers in Oxford, UK, highlights how the EXENT System can provide deeper insights into monoclonal protein biology. Their analysis identified a consistent trend in patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), where glycosylation patterns may be associated with higher risk of disease progression.

We’re proud to see this work incorporating the EXENT System represented at ASH and look forward to exploring the findings further during Saturday’s poster session (5:30 – 7:30 PM).

Discover how the EXENT System is enabling deeper exploration of monoclonal protein biology and supporting confident decision-making – visit us at booth 2171 to talk with our experts. http://spr.ly/618974hUU

We are looking forward to hearing the results of the PROMISE study that will be shared at ASH 2025 on December 6th at 4p...
05/12/2025

We are looking forward to hearing the results of the PROMISE study that will be shared at ASH 2025 on December 6th at 4pm in OCCC - West Hall E2.

The data show that Monoclonal Gammopathy of Undetermined Significance (MGUS) prevalence reaches almost 18 percent in Black individuals over fifty, emphasizing the need for ancestry-informed screening in populations at higher risk, when a monoclonal gammopathy is suspected.

Learn more about populations are at a higher risk of developing MGUS 👉 http://spr.ly/61847NmIa

Early and accurate detection of monoclonal proteins is essential to improving outcomes for patients with plasma cell dis...
04/12/2025

Early and accurate detection of monoclonal proteins is essential to improving outcomes for patients with plasma cell disorders.

Traditional electrophoretic methods have long been the standard — but limitations in sensitivity and subjectivity may lead to uncertainty in diagnosis.

Explore how Binding Site’s latest innovation, the EXENT® System, brings greater diagnostic confidence for clinicians. 👉 http://spr.ly/61887UjqI

Address

8 Calthorpe Road, Edgbaston
Birmingham
B151QT

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 5pm

Telephone

+441214569500

Website

Alerts

Be the first to know and let us send you an email when The Binding Site posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to The Binding Site:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category